Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer [Seeking Alpha]
Applied Therapeutics, Inc. (APLT)
Last applied therapeutics, inc. earnings: 11/13 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Play 13min Summary Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits in galactosemia and SORD deficiency, and its PDUFA for the former arrives at the end of November. With no AdCom, approval seems the likeliest outcome. Despite financial constraints, strong patient and HCP support suggest a successful commercial launch for govorestat, making Applied stock a “Buy” with expected valuation growth. Investors should consider potential fundraising dilution but anticipate long-term value increases and possible Big Pharma acquisition. With potential peak revenues of $500m in galactosemia, likely doubling with an anticipated approval in SORD next year, the long-term APLT “Buy” thesis appears relatively derisked. Klaus Vedfelt/DigitalVision via Getty Images Investment Overview Applied Therapeutics, Inc. NASDAQ: APLT ) stock was so
Show less
Read more
Impact Snapshot
Event Time:
APLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APLT alerts
High impacting Applied Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APLT
News
- Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA [Yahoo! Finance]Yahoo! Finance
- Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Citigroup Inc. from $8.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Applied Therapeutics, Inc. (NASDAQ: APLT) had its price target raised by analysts at Leerink Partners from $11.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
APLT
Earnings
- 8/7/24 - Miss
APLT
Sec Filings
- 8/23/24 - Form 4
- 8/23/24 - Form 4
- 8/14/24 - Form 4
- APLT's page on the SEC website